RCS - Poolbeg Pharma PLC - Immunomodulator II patent granted in Japan

Poolbeg PharmaAnnouncement

21/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231121:nRSU0473Ua&default-theme=true

RNS Number : 0473U  Poolbeg Pharma PLC  21 November 2023

Poolbeg Pharma plc

 

Immunomodulator II patent granted in Japan
Further enhancement of the patent portfolio

 

21 November 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces that the Japanese
Patent Office has notified the Company of its official decision to grant
Poolbeg's Immunomodulator II patent application.

 

The claims cover the pharmaceutical composition of POLB 001 for treating
severe influenza in a hospitalised patient in combination with antiviral
compounds, further strengthening the Company's robust intellectual property in
the territory. The formal granted patent will be received in due course.

 

In addition, further to the Company's announcement on 20 September 2023
(https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/w6m9gqx)
, it has received the fully granted patent for Immunomodulator I from the
Japanese Patent Office.

 

Poolbeg has a worldwide licence for POLB 001 for all uses in humans and is
developing a strong IP portfolio with patents in place, including
Immunomodulator I and Immunomodulator II, covering the use of the class of p38
MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of
severe influenza and the use of POLB 001 for the treatment of
hypercytokinaemia. The Company continues to seek broader patent protection for
POLB 001 and p38 MAP kinase inhibitors in general around the treatment and
prevention of severe influenza and hypercytokinemia, and has also filed patent
applications, to expand its IP around POLB 001, to the use of p38 MAP kinase
inhibitors alongside cancer immunotherapies, enhancing the value and
attractiveness of POLB 001 to potential pharma partners.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented:
"The grant received from the Japanese Patent Office highlights the progress we
are making in developing our patent portfolio. By strategically growing this
exciting molecule's intellectual property portfolio, we aim to enhance its
overall value for our partners. POLB 001 stands poised to make a substantial
impact on global health and has tremendous potential to address unmet medical
needs worldwide across multiple disease areas."

 

- Ends -

 

Enquiries

 

 Poolbeg Pharma Plc                                                      +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)        +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                    +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                                 +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                        +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                  poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

 

 

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need. Its
model focusses upon developing its exciting clinical assets and
commercialising approved and marketed drugs to fund the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team and Board have been augmented with
strong commercialisation expertise following the appointment of three former
members of the Amryt Pharma plc leadership team, with the intention of
repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets across cancer
immunotherapies, infectious disease, and an oral GLP-1 agonist for obesity and
other metabolic conditions. It uses a cost-effective development philosophy to
generate high quality human data to support partnering and further
development. Its AI-led infectious disease programmes analyse unique data from
human challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABMBRTMTATBMJ